In November 2019, FDA (Food and Drug Administration) conducted an audit at KO-MED Clinical Centers. The two FDA auditors not only discovered no critical/major findings, which is in itself a very positive signal for us but also emphasized on multiple occasions the very good organization and high standards of study conduct.

It is worth noting that the FDA auditors inspected a clinical trial studying the effectiveness of a new drug in reducing the risk of cardiovascular events in people with diabetes. The inspected study took 6 years, There were 138 randomized patients, 283 SAEs, 141 endpoints  and 18 mortalities.

Lack of any negative findings attests to the true quality and commitment of KO-MED Clinical Centers.